Polarean Imaging PLC Exercise of Warrants (6096G)
24 Julio 2019 - 8:45AM
UK Regulatory
TIDMPOLX
RNS Number : 6096G
Polarean Imaging PLC
24 July 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Exercise of Warrants
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product for the magnetic resonance imaging (MRI) market, announces
that it has issued 1,336,000 new ordinary shares of GBP0.00037 each
in the capital of the Company ("Ordinary Shares") at par value (the
"New Shares"), following the exercise of warrants by John
Sudol.
The consideration received by the Company pursuant to the
warrant exercise will be approximately US$500.
Application will be made for the New Shares, which will rank
pari passu with existing Ordinary Shares, to be admitted to trading
on AIM ('Admission'). It is expected that Admission will become
effective and dealings will commence at 8:00 a.m. on or around 29
July 2019.
Following Admission, John Sudol will hold 7,542,121 Ordinary
Shares, representing 6.6% of the Company's issued share capital
with voting rights.
Total Voting Rights
Following Admission, the total issued share capital of the
Company will consist of 114,438,600 Ordinary Shares. This number
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest, or a change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution functional
magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate than current methods. The annual
burden of pulmonary disease in the US is estimated to be over
US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCRIMJTMBJTBRL
(END) Dow Jones Newswires
July 24, 2019 09:45 ET (13:45 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024